[go: up one dir, main page]

WO1990001947A1 - Vaccin a affinite associee - Google Patents

Vaccin a affinite associee Download PDF

Info

Publication number
WO1990001947A1
WO1990001947A1 PCT/US1989/003657 US8903657W WO9001947A1 WO 1990001947 A1 WO1990001947 A1 WO 1990001947A1 US 8903657 W US8903657 W US 8903657W WO 9001947 A1 WO9001947 A1 WO 9001947A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
liposome
composition
affinity
chs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1989/003657
Other languages
English (en)
Inventor
Mircea C. Popescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of WO1990001947A1 publication Critical patent/WO1990001947A1/fr
Priority to KR1019900700840A priority Critical patent/KR900701316A/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention concerns a vaccine against an infective agent, the vaccine comprising a liposome having an exterior and an interior and having externally disposed affinity (noncovalently) associated •J ⁇ antigen material of at least one, preferably nonpartitioning, antigen representative of said infective agent. Also disclosed is a method of preparation and use of this vaccine.
  • antigens are introduced into an organism in a manner so as to stimulate an immune response in the host organism.
  • T_ ⁇ _ induction of an immune response depends on many factors among which are believed to be the chemical composition and configuration of the antigen, the potential of the immune system of the challenged organism, and the manner and period of administration of the antigen.
  • An immune response has many aspects some of which are 5 exhibited by the cells of the immune system, (e.g. ,B-lymphocytes,
  • Immune system cells may participate in the immune response through interaction with antigen, interaction with other cells of the immune system, the release of cytokines and reactivity to those cytokines. Immune response is conveniently (but arbitrarily) divided into two main categories — humoral and cell-mediated.
  • the humoral component of the immune response includes production of immunoglobulins specific for the antigen.
  • the cell-mediated component includes the generation of delayed-type hypersensitivity and cytotoxic effector cells against the antigen.
  • immune response is the result of an initial or priming dose of an antigen that is followed by one or more booster exposures to the antigen.
  • an antigen will exhibit two properties, the capacity to stimulate the formation of the corresponding antibodies and the propensity to react specifically with these antibodies.
  • Antigens bear one or more epitopes which are the smallest part of an antigen recognizable by the combining site of an antibody.
  • antigens or fractions of antigens or with particular presenting conditions the immune response precipitated by the desired antigen is inadequate or nonexistent and insufficient immunity is produced. This is particularly the case with peptide or other small molecules used as antigens.
  • the vaccine art recognizes the use of substances called adjuvants to potentiate an immune response when used in conjunction with an antigen or immunogen.
  • adjuvants are further used to elicit immune response sooner, or a greater response, or with less antigen or immunogen or to increase production of certain antibody subclasses that afford immunological protection, or to enhance components of the immune response (e.g., humoral, cellular).
  • Liposomal vaccines and adjuvancy are further discussed in U.S. Patent Application Ser. No. [Docket TLC-160/1A] toffy et al., filed on date even herewith the teachings of which are incorporated herein by reference.
  • adjuvants are Freund's Adjuvants (and other oil emulsions), Bortedella Pertussis, Lipid A (the glycophospholipid moiety of lipopolysaccharide found in Gram-negative bacteria), aluminum salts (and other metal salts), Mycobacterial products (including muramyl dipeptides), and liposomes.
  • adjuvant will be understood to mean a substance or material administered together or in conjunction with an antigen which increases the immune response to that antigen.
  • Adjuvants may be in a number of forms including emulsion (e.g., Freund's adjuvant) gels (aluminum hydroxide gel) and particles (liposomes) or as a solid material.
  • adjuvant activity can be affected by a number of factors. Among such factors are (a) carrier effect, (b) depot formation, (c) altered lymphocyte recirculation, (d) stimulation of T-lymphocytes, (e) direct stimulation of B-lymphocytes and (f) stimulation of macrophages.
  • adverse reactions include granuloma formation at the site of injection, severe inflammation at the site of injection, pyrogenicity, adjuvant induced arthritis or other autoimmune response, or oncogenic response. Such reactions have hampered the use of adjuvants such as Freund's adjuvant.
  • liposome adjuvants are utilized.
  • U.S. Patent No. 4,053,585 issued October 17, 1977 to Allison et al. states that liposomes of a particular charge are adjuvants.
  • immunomodulators e.g., cytokines such as the interleukins
  • cytokines such as the interleukins
  • Humoral immune response may be measured by many well known methods.
  • Single Radial Immunodifussion Assay (SRID), Enzyme Immunoassay (EIA) and Hemagglutination Inhibition Assay (HAI) are but a few of the commonly used assays.
  • EIA also known as ELISA (Enzyme Linked Immunoassay) is used to determine total antibodies in a sample.
  • the antigen is adsorbed to the surface of a microtiter plate.
  • the test serum is exposed to the plate followed by an enzyme linked immunogloublin, such as IgG.
  • the enzyme activity adherent to the plate is quantified by any convenient means such as spectrophotometry and is proportional to the concentration of antibody directed against the antigen present in the test sample.
  • Tests to measure cellular immune response include determination of delayed-type hypersensitivity or measuring the proliferative response of lymphocytes to target antigen.
  • Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes may be unilamellar vesicles (possessing a single bilayer membrane ) or multilameller vesicles (onion-like structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer).
  • the bilayer is composed of two lipid monolayers having a hydrophobic "tail” region and a hydrophilic "head” region.
  • the structure of the membrane bilayer is such that the hydrophobic (nonpolar) "tails" of the lipid monolayers orient toward the center of the bilayer while the hydrophilic "head” orient towards the aqueous phase.
  • the original liposome preparation of Bangham, et al. involves suspending phospholipids in an organic solvent which is then evaporated to dryness leaving a phospholipid film on the reaction vessel. Next, and appropriate amount of aqueous phase is added, the mixture is allowed to "swell,” and the resulting liposomes which consist of multilamellar vesicles (MLVs) are dispersed by mechanical means.
  • MLVs multilamellar vesicles
  • Unilamellar vesicles may be produced using an extrusion apparatus by a method described in Cullis et al., PCT Application No. WO
  • LUVETS Vesicles made by this technique, called LUVETS, are extruded under pressure once or a number of times through a membrane filter.
  • LUVETs will be understood to be included in the term "unilamellar vesicle”.
  • Another class of liposomes are those characterized as having substantially equal lamellar solute distribution. This class of liposomes is denominated as stable plurilamellar vesicles (SPLV) as defined in U.S. Patent No.
  • Lipids of net negative charge are well known in the art and include for example, phosphatidyserine, phosphatidic acid, phosphatidylglycerol.
  • Lipids of net positive charge are well known in the art and include for example, aminodiglycerides, glyceridecholine, sterylamine, trimetylsterylamine, dioctadecyl trimethylamonnio propane or in general any bilayer forming amphiphile while has a charged hydrophilic moiety.
  • lipid charge may be manipulated by a number of methods well known in the art, such as by linking the lipid to a moiety of appropriate net charge.
  • the neutral lipid cholesterol may be linked to succinic acid (negative charge) to yield cholesterol hemisuccinate (CHS) of negative charge.
  • CHS cholesterol hemisuccinate
  • the tris(hydroxymethyl)aminomethane form of CHS is designated CHS as well as CHS ,. and its application to liposomes more fully sodium discussed in U.S. Patent No. 4,721,612 the teachings of which are incorporated herein by reference. Summary of the Invention
  • This invention includes a composition comprising a liposome in noncovalent association with an externally disposed antigen and in one embodiment further comprising adjuvant or further comprising aluminum hydroxide or Lipid A.
  • Preferred antigens are nonpartitioning.
  • the antigen is hydrophilic or lipophilic.
  • the affinity association is noncovalent association and the like such as electrostatic, hydrophilic, hydrogen bonding, or other bonding related to van der Waals forces such as configurational stickiness.
  • Liposomes of this invention may be unilamellar or multilamellar.
  • liposomes comprises cholesterol hemisuccinate, phosphatidylserine, phosphatidic acid, or phosphatidylglycerol as well as aminodiglyceride, glyceridecholine, sterylamine, trimethylstearylamine, dioctadecyl trimethylammonio deravitives (e.g., 1,2 bis(oleoyloxy)-3-dioctadecyl trimethylammonio propane — "D0TAP”) or any bilayer forming amphiphile having a charged hydrophilic moiety.
  • D0TAP dioctadecyl trimethylammonio deravitives
  • Antigens include HIV or portion thereof with particular reference to PB1.
  • Antigen includes peptide, glycopeptide or glycoprotein.
  • the antigen is influenza or fragments thereof, herpes or fragments thereof, haemophilus B or fragments thereof or malaria or fragments thereof.
  • Antigens also include isolated or bioengineered fragments of viruses, bacteria, cancer cells, hormoral cells and body fluid components.
  • the invention includes a method of producing an vaccine composition comprising a liposome in affinity (noncovalent) association with an externally disposed and preferably nonpartitioning antigen comprising contacting in an aqueous solution antigen and a liposome comprising said bilayer forming material of reciprocal affinity to said antigen, such that the antigen and the liposome forms an affinity association; as well as potentially removing non-affinity associated antigen.
  • the affinity between antigen and liposome is electrostatic or hydrogen bonding or is configurational stickiness.
  • the liposome is of net negative charge and the antigen of net positive charge or the liposome is of net positive charge and the antigen of net negative charge.
  • the liposome comprises CHS.
  • the antigen comprises PB1.
  • the liposomes are subjected to shearing force.
  • This invention yet further includes a method of inducing an immune response in an animal, including a human, comprising administering to said animal a therapeutically effective amount of a composition comprising a liposome in noncovalent affinity association with an externally disposed preferably nonpartitioning antigen.
  • the method can further utilize adjuvant such as aluminum hydroxide or Lipid A.
  • adjuvant such as aluminum hydroxide or Lipid A.
  • antigen is hydrophilic or lipophilic.
  • the affinity is electrostatic, hydrogen bonding or configurational stickiness.
  • the liposome comprises cholesterol hemisuccinate, phosphatidylserine, phosphatidic acid, phosphatidylglycerol as well as aminodiglyceride, glyceridecholine, stearylamine, trimetylstearylamine, dioctadecyl trimethylammonio derivatives or any bilayer forming amphiphile having a charged hydrophilic moiety.
  • Antigens can comprise HIV or portion thereof or PB1.
  • Variously antigens are noted to be protein, peptide glycopeptide or glycoprotein, polypeptide, poly(amino acid) and will be termed, collectively, "peptide”.
  • antigens influenza or fragments thereof herpes or fragments thereof, haemophilus B or fragments thereof or malaria or fragments thereof as well as isolated or bioengineered fragments of viruses, bacteria, cancer cells, hormoral cells and body fluid components.
  • Adjuvant shall mean a substance or material to potentiate an immune response when used in conjunction with an antigen or immunogen. Adjuvants are further used to elicit immune response
  • Antigen shall mean a substance or material that is recognized specifically by an antibody and/or combines with an antibody. Particular note is made of both natural and bioengineered antigens
  • j _5 such as peptides, glycopeptides and glycoproteins.
  • Specific antigens include antivirals such as herpes, hepatitis, rabies, parainfluenza, measles, mumps, respiratory syncytial virus; antibacterials such as pneumonia, haemophilis B, .staphylococcus, meningococcus, Neisseria gonorrhea; and protozoa such as malaria or 0 fragments thereof.
  • Epitope shall mean the smallest part of an antigen recognizable by the combining site of an immunoglobulin.
  • Externally disposed shall, in referring to antigen or immunogen, mean, positioned by an "affinity association" so as to bear an epitope external to the outermost lamella of an associated liposome. Included are epitopes ionically associated with the liposome, nonpartitioned into the outermost lamellae, and with 0 epitope exposed.
  • Affinity association shall mean noncovalent intermolecular associations such as electrostatic association, hydrogen bonding, and configurational stickiness. 5
  • Nonpartitioning refering to antigen or immunogen refers to hydrophilic immunogens and those lipophilic immunogens the epitopes of which are not substantially incorporated into the outermost lamella of a liposome. Those lipophilic immunogens that can be separated from liposomes by physical manipulation such as by dialysis, charge manipulation or other equilibrium based separations are deemed to be not substantially incorporated into the lamellae and nonpartitioning.
  • Immune response shall mean a specific response of the immune system of an animal to antigen or immunogen. Immune response may include the production of antibodies.
  • Immunity shall mean a state of resistance of a subject animal to a infecting organism or substance. It will be understood that infecting organism or substance is defined broadly and includes parasites, toxic substances, cancers and cells as well as bacteria and viruses. A Therapeutically Effective Immunization Course will be described.
  • Immunization conditions shall mean factors which affect an immune response including amount and kind of antigen or adjuvant 25 delivered to a subject animal, method of delivery, number of inoculations, interval of inoculation, the type of subject animal and its presenting condition.
  • Immunization dose shall mean the amount of antigen or 30 immunogen needed to precipitate an immune response. This amount will vary with the presence and effectiveness of various adjuvants. This amount will vary with the animal and immunogen or antigen or adjuvant but will generally be between about 0.lug/ml or less to about 500ug per inoculation.
  • the immunization dose is easily ⁇ ⁇ ' determined by methods well known to those skilled in the art, &uch as by conducting statistically valid host animal immunization and challenge studies. See, for example, Manual of Clinical Immunology. H.R. Rose and H. Friedman, American Society for Microbiology, Washington, D.C. (1980). In some instances several immunization doses including booster doses will be administered to provide immunity.
  • Immunogen shall mean a substance or material (including antigens) that is able to induce an immune response alone or in conjunction with an adjuvant. This will generally be a protein, peptide, polysaccharide, nucleoprotein, lipoprotein, synthetic polypeptide, or hapten linked to a protein, peptide, polysaccharid ⁇ , nucleoprotein, lipoprotein or synthetic polypeptide or other bacterial, viral or protozoal fractions.
  • immunogen includes substances which do not generate an immune response (or generate a only therapeutically ineffective immune response) unless associated with an adjuvant (e.g., small peptides) which will be referred to as "adjuvant-obligatory" immunogens.
  • adjuvant e.g., small peptides
  • infectious agent shall mean an disease causing agent including fungi, bacteria, viruses and parasites.
  • “Mimetic”, in relation to antigens, immunogens and epitopes, shall mean that refers to a moiety (either natural or synthetic) that duplicates by structure, accessibility or reactivity the response of B-cell immuno-receptors to the subject antigen in native state configuration or epitope in native state configuration.
  • “Native state configuration” shall mean that organization of a moiety as it is when present in situ in its usual condition, to be distinguished from non-native state configuration (denatured) wherein the moiety is altered as to immuno-reactivity from that of the in situ organization.
  • Vaccine shall mean a pharmaceutical formulation which induces immune response or immunity in a subject animal.
  • Antigens or immunogens may have a net positive or negative charge, or be neutral.
  • the net charges are easily determined by a number of techniques well known in the art. For peptides the net charge may assessed through determination of the isoelectric point. Peptides of isoelectric points of about 5 or less have net negative charge and the peptides are soluble in basic solution. Isoelectric points of about 8 or more indicate a net positive charge and the peptides are soluble in acid solution. Isoelectric points from 5 to 8 indicate generally neutral peptides (frim slightly acidic to slightly basic).
  • Net charges on peptides can be manipulated by a number of methods well known in the art including adding charge bearing amino acids or amino acid segments.
  • lysine and arginine add positive charge while aspartic and glutamic acid add negative charge.
  • antigens or immunogens including addition of amino acids or exposure to acidic or basic solutions or temperature variation or light that conditions must not be such as to compromise immunogenicity or native state configuration.
  • a particularly useful immunogen is the PB1 fraction of the HIV 1 virus (Repligen Corporation, Cambridge, MA). This fraction is characterized in "HTLV-III/LAV-Neutralizing Antibodies of an E. coli-Produced Fragment of the Virus Envelope", Putney, et al., Science. 234:1392-5 (1986) the teachings of which are incorporated herein by reference.
  • PB1 peptide is soluble in aqueous solution containing solubilizing substances such as urea and detergents and was supplied in such solution. Such solubilization substances were incompatible with pharmaceutical preparations and a dialysis process was utilized to remove them.
  • Antigens or immunogens which partition into the liposome lamellae such as melanoma antigen in CHS liposomes may not yield a sufficient immunogenic response with out repeated inoculation and additional adjuvant. Without being bound by any particular theory it is believed that this partitioning results in the limitation of exposure of epitopes externally to the adjuvant liposomes. Modification (e.g., conjugation with a nonpartitioning moiety) of such an antigen or immunogen while preserving native state configuration acts so as to prevent partitioning. In addition it can be advantageous to utilize both affinity associated antigen and entrapped antigen in a particular composition, vaccine or dosage form.
  • a preferred vaccine of this invention is a liposome organized so as to have an immunogen in electrostatic association with the exterior of said liposome.
  • the preferred liposome may be multilamellar (e.g., multilamellar vesicles or stable plurilamellar vesicles).
  • the vaccine contains externally disposed antigen or immunogen in such electrostatic association.
  • the most successful immunogens will be those purified from (or duplicative or mimetic of) the infective agent while maintaining immunogen native state configuration. It is understood that some vaccines are prepared without resort to living infective organisms due the potential for contamination of the final vaccine. It is thus useful to produce immunogens synthetically (including bioengineering) such as through techniques of recombinant DNA technology, recombinant RNA technology or other synthesis in host cells, but it is preferable that even synthetically produced immunogens be of native state configuration.
  • lipid and antigen of reciprocal affinity is simply accomplished by those skilled in the art. Depending upon the type of noncovalent affinity association applicable various association techniques are used. For hydrogen bonding the elevation of temperature of the aqueous solution suspending antigen and liposomes above the transition temperature of the affinity bonded entities is effective. For van der Waals, or electrostatic or configurational stickiness admixing of the antigen and liposomes in aqueous solution is sufficient, but as to electrostatic affinity the liposome and antigen are of opposite charge. Degree of affinity association of nonpartitioning antigen or immunogen is simply determined by methods well known in the art.
  • the relative attachment and nonattachment is determined by centrifuging the liposomes and antigen or immunogen admixture and then determining the amount of antigen or immunogen in the supernatant. The amount not in the supernatant being a measure of the amount affinity attached.
  • a vaccine may generate a weak immune response that is not greatly potentiated on secondary challenge. However, after a first administration of the adjuvant-associated immunogen, a substantial immune response is generated upon application of a second inoculation of the adjuvant free immunogen in solution.
  • Table 1 presents the data of an experiment in which CHS. . tris formulation was compared with other liposome formulations.
  • Liposomes made of CHS . (Table 1, group F) were prepared by _.r s multilamellar vesicles (MLV) procedure. This formulation involves the coating of the surface of negatively charged liposomes with the positively charged antigen.
  • Liposomes made of dimyristolyphosphatidylcholine/cholesterol were prepared using either stable plurilamellar vesicle (SPLV) procedure (D-W, D) or monophasic vesicle (MPV) procedure (D-E, D-T).
  • SPLV plurilamellar vesicle
  • MPV monophasic vesicle
  • DMPC (80 mg) and cholesterol (20 mg) in 1 ml chloroform were rotoevaporated under vacuum to a dry film and further solubilized in 5 ml ether + 0.5 ml ethanol at 40°C for a few seconds until the solution was clear.
  • the PB1 antigen (100 ug) in 0.5 ml 1% acetic acid was added to this solution and the resulting mixture was sonicated under a stream of N at 40°C for about 1 minute until dryness under stream (2-3 minutes).
  • the resulting dry material was resuspended in 10 ml phosphate buffered saline minus Ca ++ and Mg++ (KC1 2g/L,
  • This liposome was prepared as described above for the D-W liposome except that the centrifugation step was omitted. Subsequently the material dried by N law stream was resuspended in 2 ml PBS minus to a final concentration of 50 mg lipid and 50 ug antigen/ml.
  • Cholesterol (20 mg) was dissolved in 1 ml ethanol containing 80 mg solubilized DMPC by brief heating to 40°C (10-20 sec.) and stirring.
  • the solution of antigen (1 ml) was prepared separately by mixing 100 ug PB1 in 0.13 ml 1% acetic acid and 0.87 ml ethanol and immediately mixed with the lipid solution. The mixture was rotoevaporated under vacuum at 40°C and the resulting material was resuspended in 2 ml PBS minus by sonication for 10 seconds at 40°C to a final suspension of 50 mg lipid and 50 ug antigen/ml.
  • This liposome was prepared as described above for the D-E liposome except that the ethanol was replaced by Tert-butyl-alcohol (TBA) .
  • TSA Tert-butyl-alcohol
  • This preparation was done by mixing 0.5 ml of SPLV, liposome D made of DMPC/CHOL and 0.5 ml of empty MLV liposome H made of
  • the mixture contained 75 mg tris lipids (50 mg CHS , 25 mg DMPC/CHOL) and 25 ug PBl
  • CFA complete Freund's adjuvant
  • This emulsion was prepared as described above except that PBl antigen was not dialyzed.
  • PBl ata concentration of 0.77 mg/ml in a 50 mM phosphate buffer, pH 6.8, containing 2 mM EDTA, 10 mM DTT and 8 M urea was diluted in PBS minus to 50 ug/ml.
  • Stock PBl solution (0.77mg/ml in a 50 mM phosphate buffer, pH _ 6.8, containing 2 mM EDTA, 10 mM dithiothetrol and 8 m urea) was dialyzed against 1% acetic acid (pH 2.5) and the dialyzed antigen diluted before use in PBS minus at 50 ug/ml.
  • mice Balb/C (Jakson), 6-8 weeks old female mice were inoculated intramuscularly ("IM") at day 0, 15, 35 and blood was taken at day 0, 14, 28, 49, 63 and 79.
  • the dose of antigen was 5 ug/0.1 ml/inoculum except group E which received 2.5 ug.
  • PBl specific antibody IgG and IgM was determined by a standard ELISA procedure.
  • the amount of Alum was kept constant at 0.4 mg/ml of physiological saline (USP).
  • the CHS liposome-PBl formulations were prepared as described previously (group F, table 3).
  • a formulation containing 50 ug antigen/ml was further diluted in a suspension of empty CHS liposomes in PBS minus such that the amount of lipids was kept constant at 50 mg/ml and the antigen decreased to 2.5, 1.25 and 0.31 ug/ml.
  • Another CHS formulation at 50 mg lipid and 20 ug antigen was subjected to shearing force via vortexing and sonicating at low energy intermittently for 2 hours at room temperature in order to achieve a suitable suspension.
  • Vaccines are conveniently administered in a dosage form.
  • a "dosage form” will be understood to mean any pharmaceutically form of administering a vaccine including subcutaneous, oral, intramuscular, and ocular administration and utilizing vaccines in live, attenuated or synthetic or bioengineered or partial forms along with adjuvants and optionally immunomodulators such as cytokines.
  • the combinations of the foregoing elements are prepared so that the dosage form is adapted to produce a therapeutically effective immune response in the subject animal including a human as easily and effectively as possible.
  • the dosage forms including liposomal dosage forms resulting from the method of the present invention can be used therapeutically in mammals, including a human, in the treatment of infections or conditions which require the delivery of immunogen in its bioactive form. Such conditions include but are not limited to disease states such as those that can be treated or prevented with vaccines.
  • Dosage forms also include use of adjuvant as well as vaccine incorporated into gel such as aluminum gels, lipids such as Lipid A, liquid crystals, powders, precipitates and solutions.
  • the dosage form can be a unit dosage form configured and adapted to a single administration.
  • the mode of administration of the dosage form may determine the sites and cells in the organism to which the dosage form will be delivered.
  • the dosage forms including liposomal dosage forms of the present invention can be administered alone but will generally be administered In admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • the dosage forms may be injected intramuscuarly, subcutaneously or intradermally.
  • the dosage forms may also be administered via oral routes routes.
  • parenteral administration they can be used, for example, in the form of a sterile aqueous solution which may contain other solutes, for example, enough salts or glucose to make the solution isotonic. Other uses, depending upon the particular properties of the preparation, may be envisioned by those skilled in the art.
  • PBl is a positively charged peptide and thus dialysis of PBl from stock solution was performed against a 1% acetic acid at a pH of 2.5. Upon dialysis the PBl remained soluble for several hours in 1% acetic acid. It was noted that, were the pH to approach neutral pH, the PBl antigen would rapidly preciptiate. Affinity attachment of the PBl to liposomes was accomplished by utilizing a liposome of reciprocal (here negative) charge. CHS . liposomes having a negative charge were used, suspended in neutral (pH 7.2) buffer and then mixed with the PBl in 1% acetic acid solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un vaccin contre un agent d'infection, le vaccin comprenant un liposome ayant un extérieur et un intérieur et ayant un matériau antigène associé à une affinité extérieure d'au moins un antigène de préférence de non-cloisonnage représentatif dudit agent infectieux. Un procédé de préparation de ce vaccin ainsi que son utilisation sont décrits.
PCT/US1989/003657 1988-08-25 1989-08-24 Vaccin a affinite associee Ceased WO1990001947A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019900700840A KR900701316A (ko) 1988-08-25 1990-04-25 친화력 결합백신

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23670288A 1988-08-25 1988-08-25
US23670188A 1988-08-25 1988-08-25
US236,702 1988-08-25
US236,701 1988-08-25
USNOTFURNISHED 1990-12-03

Publications (1)

Publication Number Publication Date
WO1990001947A1 true WO1990001947A1 (fr) 1990-03-08

Family

ID=26930035

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1989/003658 Ceased WO1990001948A1 (fr) 1988-08-25 1989-08-24 Vaccin contre la grippe et nouveaux adjuvants
PCT/US1989/003657 Ceased WO1990001947A1 (fr) 1988-08-25 1989-08-24 Vaccin a affinite associee

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1989/003658 Ceased WO1990001948A1 (fr) 1988-08-25 1989-08-24 Vaccin contre la grippe et nouveaux adjuvants

Country Status (2)

Country Link
KR (1) KR900701316A (fr)
WO (2) WO1990001948A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010198A1 (fr) * 1992-11-02 1994-05-11 Yves Claude Nicolau Procede de reduction de la resistance a plusieurs medicaments dans des cellules et des tissus
US6096307A (en) * 1997-12-11 2000-08-01 A. Glenn Braswell Compositions for immunostimulation containing Echinacea angustofolia, bromelain, and lysozyme
JP2002537271A (ja) * 1999-02-17 2002-11-05 シーエスエル、リミテッド 免疫原複合体およびそれに関する方法
EP1239876A4 (fr) * 1999-11-19 2003-05-02 Csl Ltd Compositions vaccinales

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4136553A1 (de) * 1991-11-06 1993-05-13 Biotechnolog Forschung Gmbh Impfstoff gegen schleimhauterreger und herstellungsverfahren
EA017441B1 (ru) 2006-06-15 2012-12-28 Новартис Аг Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4826687A (en) * 1985-06-06 1989-05-02 National Institute Of Health Influenza vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
HU184141B (en) * 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4745074A (en) * 1984-02-23 1988-05-17 Cooper-Lipotech Partnership Blood-fluid composition for cell lysis system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4826687A (en) * 1985-06-06 1989-05-02 National Institute Of Health Influenza vaccine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGY LETTERS, Volume 14, issued in 1986/1987, DAVIS D. et al., "Liposomes as Adjuvants with Immunopurified Tetanus Toxoid: the Immune Response", pages 346-347. *
IMMUNOLOGY, Volume 61, issued in 1987, DAVIS D. et al., "Liposomes as Adjuvants with Immunopurified Tetanus Toxoid: the Influence of Liposomal Characteristics", pages 230 and 232. *
INFECTION AND IMMUNITY, Volume 56, issued in 1988, RICHARDS R., "Liposomes, Lipid A and Aluminum Hydroxide Enhance the Immune Response to a Synthetic Malaria Sporozite Antigen", page 684. *
OSTRO M., ed., "Liposomes: From Biophysics to Therapeutics", published 1987, (MARCEL DEKKER, NEW YORK), ALVING C., "Liposomes as Carriers for Vaccines", pages 195-201. *
VACCINE, Volume 4, issued in 1986, ALVING C., "Effectiveness of Liposomes as Potential Carriers of Vaccines: Applications to Cholera Toxin and Human Malaria Sporozite Antigen", pages 166-167. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010198A1 (fr) * 1992-11-02 1994-05-11 Yves Claude Nicolau Procede de reduction de la resistance a plusieurs medicaments dans des cellules et des tissus
US6096307A (en) * 1997-12-11 2000-08-01 A. Glenn Braswell Compositions for immunostimulation containing Echinacea angustofolia, bromelain, and lysozyme
JP2002537271A (ja) * 1999-02-17 2002-11-05 シーエスエル、リミテッド 免疫原複合体およびそれに関する方法
EP1150710A4 (fr) * 1999-02-17 2003-09-03 Csl Ltd Complexes immunogenes et methodes y relatives
AU783344B2 (en) * 1999-02-17 2005-10-20 Csl Limited Immunogenic complexes and methods relating thereto
EP2204186A1 (fr) * 1999-02-17 2010-07-07 Csl Limited Complexes immunogènes et méthodes y relatives
EP1239876A4 (fr) * 1999-11-19 2003-05-02 Csl Ltd Compositions vaccinales

Also Published As

Publication number Publication date
WO1990001948A1 (fr) 1990-03-08
KR900701316A (ko) 1990-12-01

Similar Documents

Publication Publication Date Title
AU631377B2 (en) Affinity associated vaccine
US5916588A (en) Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) Potentiation of immune responses with liposomal adjuvants
US5100662A (en) Steroidal liposomes exhibiting enhanced stability
EP0356340B1 (fr) Vaccin à affinité associée
CA2086831C (fr) Virosomes de la grippe reconstitues par immunostimulation et immunopotentialisation et vaccins contenant ceux-ci
CA2258878C (fr) Composition de vaccin contre la grippe encapsulee dans des liposomes et leur procede de fabrication
JP5519477B2 (ja) Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
CA2169297C (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
EP0542923B1 (fr) Liposomes fournissant une aide thymodependante a des antigenes de vaccin faibles
US5897873A (en) Affinity associated vaccine
CA2157125A1 (fr) Systeme d'inoculation de vaccin et solution de precurseur stable au stockage pour encapsulation a distance d'ingredients actifs
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
WO1990001947A1 (fr) Vaccin a affinite associee
Kramp et al. Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines
CA1334165C (fr) Vaccin avec antigenes associes par affinite
Dijkstra et al. Interaction of liposome-incorporated lipopolysaccharide with responsive cells
Gregoriadis et al. The immunoadjuvant action of liposomes: role of structural characteristics
KR0137360B1 (ko) 인플루엔자 백신과 새로운 보조제
Dijkstra et al. Volume I: Molecular Biochemistry and Cellular Biology 329
JP2004161781A (ja) 経口ワクチン
HK1008304B (en) Liposomes that provide thymic dependent help to weak vaccine antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP KR